CD276 (B7-H3) Monoclonal Antibody (M3.2D7), Biotin, eBioscience™, Invitrogen™

Description

• Description: The M3.2D7 monoclonal antibody was generated against and reacts with mouse B7-H3, a member of the B7 family of the Ig superfamily proteins
• B7-H3 is reported to be expressed by antigen presenting cells and developing bone during embryogenesis
• The ligand for B7-H3 has not yet been identified and it is thought that B7-H3 down-regulates T cell functions by engaging an unknown counter receptor on T cells
• M3.2D7 stains mouse B7-H3 transfected cells and not mouse spleen cells
• M3.2D7 also stains human B7-H3 transfected cells
• Applications Reported: The M3.2D7 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The M3.2D7 antibody has been tested by flow cytometric analysis of mB7-H3 transfected cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Filtration: 0.2 μm post-manufacturing filtered
• CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3
• CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma
• Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon
• In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing
• CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.